BioAge Labs, Inc. (BIOA) dividends
BIOA on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
BioAge Labs, Inc. dividend: key facts
Own BioAge Labs, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next BIOA dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- BioAge Labs to Present at Upcoming Investor Conferences11 Nov 2026 · GlobeNewsWire
EMERYVILLE, Calif., Nov. 11, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates f...
- BioAge Labs price target lowered to $40 from $73 at Piper Sandler9 Nov 2026 · TheFly
Piper Sandler analyst Yasmeen Rahimi lowered the firmâs price target on BioAge Labs (BIOA) to $40 from $73 and keeps an Overweight rating on the shares. Ziltivekimabâs Phase 3 ZEUSâ¦
- BioAge Labs reports Q3 EPS (73c), consensus (63c)6 Nov 2026 · TheFly
Reports Q3 revenue $298,000, consensus $1.48M. âNLRP3 is a key switch that turns on inflammation and drives multiple diseases. Injectable drugs that block two major inflammatory signals, IL-1 and IL-6...
- BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates6 Nov 2026 · GlobeNewsWire
First participant dosed in QUELL-DME, a Phase 2 trial of BGE-102, a potential best-in-class oral NLRP3 inhibitor, in diabetic macular edema; topline results anticipated in the second half of 2027
- BioAge Labs initiated with a Neutral at UBS17 Oct 2026 · TheFly
UBS analyst Alice Nettleton initiated coverage of BioAge Labs (BIOA) with a Neutral rating and $8 price target While the companyâs lead asset BGE-102 would be a differentiated NLRP3 inhibitor,â¦
- Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target17 Oct 2026 · GlobeNewsWire
Partnership applies Deep Origin's virtual screening architecture to BioAge's targets, identified from human data, to accelerate discovery of novel cardiometabolic therapies Partnership applies Deep Or...
- BioAge Labs doses first patient in QUELL-DME study15 Sep 2026 · TheFly
BioAge Labs (BIOA) announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial evaluating once-daily oral BGE-102 in adults with diabetic macular edema. Th...
- BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema15 Sep 2026 · GlobeNewsWire
Randomized, controlled, approximately 180-participant trial evaluates oral BGE-102 as monotherapy and in combination with anti-VEGF therapy Primary endpoint is change in best-corrected visual acuity a...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.